Australia markets closed
  • ALL ORDS

    7,248.10
    -193.40 (-2.60%)
     
  • AUD/USD

    0.7141
    -0.0005 (-0.07%)
     
  • ASX 200

    6,961.60
    -177.90 (-2.49%)
     
  • OIL

    83.82
    +0.51 (+0.61%)
     
  • GOLD

    1,842.30
    +0.60 (+0.03%)
     
  • BTC-AUD

    50,470.28
    +1,056.15 (+2.14%)
     
  • CMC Crypto 200

    818.44
    +7.84 (+0.97%)
     

REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • RETA

NEW YORK, December 09, 2021--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns whether Reata has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On December 6, 2021, the U.S. Food and Drug Administration ("FDA") released a briefing document regarding Reata’s chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not "demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome]."

On this news, Reata’s stock price fell $29.77 per share, or 37.8%, to close at $48.92 per share on December 6, 2021.

If you purchased or otherwise acquired Reata shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006153/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting